$Transcode Therapeutics (RNAZ.US)$
TransCode's progression to the fourth dosing cohort represents a typical risk-reduction event for a small-cap biotech with a $797,205 market cap. The unanimous Safety Review Committee approval indicates the trial is executing according to plan, which is particularly important for cash-constrained companies like TransCode where clinical delays can significantly impact runway.
The absence of safety concerns across three dosing cohorts d...
TransCode's progression to the fourth dosing cohort represents a typical risk-reduction event for a small-cap biotech with a $797,205 market cap. The unanimous Safety Review Committee approval indicates the trial is executing according to plan, which is particularly important for cash-constrained companies like TransCode where clinical delays can significantly impact runway.
The absence of safety concerns across three dosing cohorts d...
1
$Transcode Therapeutics (RNAZ.US)$
TransCode's advancement to Cohort 4 in their Phase I/II trial represents a standard but necessary milestone in the clinical development of TTX-MC138. The absence of dose-limiting toxicities across all three previous cohorts is encouraging for an RNA therapeutic targeting metastatic cancer, allowing for the planned 50% dose increase in Cohort 4.
The retention of 6 out of 9 patients from earlier cohorts for continued treatment sign...
TransCode's advancement to Cohort 4 in their Phase I/II trial represents a standard but necessary milestone in the clinical development of TTX-MC138. The absence of dose-limiting toxicities across all three previous cohorts is encouraging for an RNA therapeutic targeting metastatic cancer, allowing for the planned 50% dose increase in Cohort 4.
The retention of 6 out of 9 patients from earlier cohorts for continued treatment sign...
2
Teddy123
commented on
$Aditxt (ADTX.US)$ i bought 10k of share at 0.128. this is pathetic should I let go ? 🥲🥲🥲🥲🥲
9
Teddy123
reacted to
$KULR Technology (KULR.US)$
pump it up guys!!!
pump it up guys!!!
2